As AbbVie Inc. ABBV looks to plug holes in the sales of its mega-blockbuster arthritis drug Humira, newer immunology drugs will be key to the pharmaceutical giant’s future growth, analysts say. When ...
Hosted on MSN
Coherus Biosciences Divests UDENYCA Business
An update from Coherus Biosciences ( (CHRS)) is now available. On April 11, 2025, Coherus Biosciences sold its UDENYCA business, marking a significant divestiture of its biosimilar businesses, which ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback